Based on work of Svetomir Markovic and colleagues at the Mayo Clinic^2,3

Enables the binding of antibodies to drug payloads for oncology and beyond

Circumvents the need for:

• Use of covalent “linker” technology
• Internalization into the cell

Known, clinically active antibodies are non-covalently bound to drug payloads by construction of a patented admixture of

• One or more therapeutically or immunologically active antibodies 
• A “particle” of albumin
• The drug payload

Investigator initiated proof of concept studies are ongoing in B cell lymphoma, melanoma, and gynecological cancers

Intellectual property portfolio comprised of 17 patent families, 32 patents granted to date with life through at least 2035 and another 135 patents pending.